Source comparison
Libido Peptides Women PT-141 Hormonal Support: Comparison
PT-141 (bremelanotide) MC4R agonist in hypothalamus. Activates desire pathways centrally 45–90 minutes (on-demand dosing) Premenopausal women with acquired, generalized HSDD. Normal or low hormone levels Nausea (40%), flushing (20%), transient BP elevation Fir
This comparison does not assign a generated winner or score.
- PT-141 (bremelanotide)
- MC4R agonist in hypothalamus. Activates desire pathways centrally
- 45–90 minutes (on-demand dosing)
- Premenopausal women with acquired, generalized HSDD. Normal or low hormone levels
- Nausea (40%), flushing (20%), transient BP elevation
- First-line option for women with desire impairment despite intact arousal and normal hormonal profiles
- Testosterone (patch/gel)
- Androgen receptor activation. Increases baseline sexual thoughts and genital sensitivity
- 4–8 weeks of daily dosing
- Postmenopausal women with documented low testosterone (<15 ng/dL) and HSDD
- Acne, hirsutism, voice deepening (dose-dependent)
- Effective only when androgen deficiency is confirmed. No benefit in women with normal testosterone
- Estrogen (systemic or vaginal)
- Estrogen receptor activation. Restores vaginal tissue elasticity and lubrication
- 2–6 weeks for tissue effects
- Postmenopausal women with vaginal atrophy and dyspareunia
- Breast tenderness, endometrial hyperplasia risk (systemic)
- Addresses arousal and pain barriers but does not restore desire independently
- Flibanserin (Addyi)
- 5-HT1A agonist / 5-HT2A antagonist. Modulates serotonergic tone over time
- Premenopausal women with generalized HSDD. Requires continuous use
- Hypotension, syncope (especially with alcohol), somnolence
- Daily medication with modest effect size. Black-box warning limits practical use
- DHEA (intravaginal)
- Local androgen precursor conversion. Improves vaginal tissue and genital sensitivity
- 8–12 weeks
- Postmenopausal women with vaginal atrophy and reduced genital arousal
- Minimal systemic effects. Rare vaginal discharge
- Targets arousal and lubrication, not central desire pathways